Administration practices of and adherence to nusinersen in children with spinal muscular atrophy: a multicenter disease registry study in China

BackgroundNusinersen was the first approved disease modifying therapy (DMT) for spinal muscular atrophy (SMA). Intrathecal administration of nusinersen enables drug delivery directly to the central nervous system, where the motor neurons are located. Per the package insert, individuals with SMA receive 4 loading doses of nusinersen followed by maintenance doses every 4 months thereafter. The aim of this analysis was to investigate the administration practices of and adherence to nusinersen in Chinese children with SMA.MethodsData were analyzed from a longitudinal, multicenter registry enrolling children with 5q-SMA in China. Information on nusinersen administration, including administration date, care setting, use of sedation and general anesthesia, method of administration, and use of imaging guidance before administration, was collected both retrospectively and prospectively. Adherence rate was calculated at dose and participant level. A dose was considered adherent if the inter-dose interval (for dose-level) and interval from the first dose (for participant-level) followed the standard dosing regimen, with a grace period of +/- 7 days for Dose 2 to 4 and +/- 28 days thereafter.ResultsA total of 385 participants receiving nusinersen with a total of 2,415 doses were included in the study. The median (interquartile range) number of doses administered per participant was 6 (5-7). Over 99% of intrathecal injections were given in an inpatient setting. Only a few (n = 3, 0.1%) required general anesthesia, while 9% (n = 217) of doses were administered under the use of sedation. Interlaminar lumbar puncture (n = 2,407, 99.7%) was the most common method of administration, followed by cervical puncture (n = 5, 0.2%) and transforaminal lumbar puncture (n = 3, 0.1%). Over 90% of injections did not utilize any imaging guidance prior to administration, with ultrasound (n = 142, 5.9%) being the most commonly used imaging guidance. The adherence rate was 95.7% (1,943/2,030) at dose level and 81.0% (312/385) at participant level. The median inter-dose intervals aligned well with the dosing schedule, with 14 days for Doses 2 and 3, 35 days for Dose 4, and 114-124 days for maintenance doses thereafter.ConclusionsFindings from the analysis demonstrated high real-world adherence to nusinersen in Chinese children with SMA.